Rifampin Use and Safety in Hospitalized Infants

Christopher J. Arnold, Jessica Ericson, Jordan Kohman, Kaitlyn L. Corey, Morgan Oh, Janet Onabanjo, Christoph P. Hornik, Reese H. Clark, Daniel K. Benjamin, P. Brian Smith, Vivian H. Chu

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Objective This study aims to examine the use and safety of rifampin in the hospitalized infants. Study Design Observational study of clinical and laboratory adverse events among infants exposed to rifampin from 348 neonatal intensive care units managed by the Pediatrix Medical Group between 1997 and 2012. Result Overall, 2,500 infants received 4,279 courses of rifampin; mean gestational age was 27 weeks (5th, 95th percentile; 23, 36) and mean birth weight was 1,125g (515; 2,830). Thrombocytopenia (121/1,000 infant days) and conjugated hyperbilirubinemia (25/1,000 infant days) were the most common laboratory adverse events. The most common clinical adverse events were medical necrotizing enterocolitis (64/2,500 infants, 3%) and seizure (60/2,500 infants, 2%). Conclusion The overall incidence of adverse events among infants receiving rifampin appears low; however, additional studies to further evaluate safety and dosing of rifampin in this population are needed.

Original languageEnglish (US)
Pages (from-to)565-570
Number of pages6
JournalAmerican Journal of Perinatology
Issue number6
StatePublished - May 1 2015

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology


Dive into the research topics of 'Rifampin Use and Safety in Hospitalized Infants'. Together they form a unique fingerprint.

Cite this